A randomized, multicenter, open-label controlled phase 2 trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer

JEM–X inflight performance

We summarize the inflight performance of JEM-X, the X-ray monitor on the INTEGRAL mission during the initial ten months of operations. The JEM-X instruments have now been tuned to stable operational conditions. The performance is found to be close to the pre-launch expectations. The ground calibrations and the inflight calibration data permit to determine the instruments characteristics to fully support the scientific data analysis. Reglero Velasco, Victor, Victor.Reglero@uv.es ; Martinez Nuñez, Silvia, Silvia.Martinez@uv.es